{"content":"<li class=\"n-box-item date-title\" data-end=\"1479963599\" data-start=\"1479877200\" data-txt=\"Sunday, December 22, 2019\">Wednesday, November 23, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3226796\" data-ts=\"1479945009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRP\" target=\"_blank\">CTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226796-ctripplus-10-after-earnings-skyscanner-purchase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ctrip +10% after earnings, Skyscanner purchase</a></h4><ul>     <li>Ctrip.com (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CTRP\" title=\"Ctrip.com International, Ltd.\">CTRP</a>) <font color=\"green\">+10.1%</font> AH after reporting better than expected <a href=\"https://seekingalpha.com/news/3226792-ctrip-com-beats-0_09-beats-revenue\" target=\"_blank\">Q3 earnings</a> and revenues, and guiding Q4 revenues above consensus; the online travel company also announces an agreement to acquire Skyscanner Holdings in a deal that values the travel search website for ~£1.4B ($1.74B).</li>\n<li>Skyscanner serves 60M monthly active users and is available  in more than 30 languages.</li>\n<li>Ctrip says Q3 non-GAAP operating margin was 18%, its best showing since early 2014, driven by operating efficiency improvements across the board.</li>\n<li>Ctrip also now sees Q4 revenues of $754M-$776M (+70%-75% Y/Y) vs. $745M analyst consensus estimate.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3226796\" data-linked=\"Ctrip +10% after earnings, Skyscanner purchase\" data-tweet=\"$CTRP $TCOM - Ctrip +10% after earnings, Skyscanner purchase https://seekingalpha.com/news/3226796-ctripplus-10-after-earnings-skyscanner-purchase?source=tweet\" data-url=\"https://seekingalpha.com/news/3226796-ctripplus-10-after-earnings-skyscanner-purchase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226792\" data-ts=\"1479942243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTRP\" target=\"_blank\">CTRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226792-ctrip-com-beats-0_09-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ctrip.com beats by $0.09, beats on revenue</a></h4><ul>\n<li>Ctrip.com (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CTRP\" title=\"Ctrip.com International, Ltd.\">CTRP</a>): Q3 EPS of $0.01 <font color=\"green\">beats by $0.09</font>.</li>\n<li>Revenue of $836M (+66.9% Y/Y) <font color=\"green\">beats by $25.13M</font>.</li>\n<li>Shares <font color=\"green\">+4.9%</font> AH.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226792\" data-linked=\"Ctrip.com beats by $0.09, beats on revenue\" data-tweet=\"$CTRP $TCOM - Ctrip.com beats by $0.09, beats on revenue https://seekingalpha.com/news/3226792-ctrip-com-beats-0_09-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3226792-ctrip-com-beats-0_09-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226778\" data-ts=\"1479935836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCON\" target=\"_blank\">TCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226778-tracon-pharma-launches-15m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TRACON Pharma launches $15M stock offering</a></h4><ul>\n<li>Thinly traded nano cap TRACON Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/TCON\" title=\"Tracon Pharmaceuticals\">TCON</a>) <a href=\"https://www.sec.gov/Archives/edgar/data/1394319/000156459016029616/tcon-8k_20161123.htm\" target=\"_blank\">initiates </a>a public offering of 2.625M shares of common stock at $5.75. Underwriters over-allotment is an additional 393,750 shares. Closing date is November 29. Gross proceeds should be ~$15.1M.</li>\n<li>Today's close was $6.00 so investors should expect a down day on Friday.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226778\" data-linked=\"TRACON Pharma launches $15M stock offering\" data-tweet=\"$TCON - TRACON Pharma launches $15M stock offering https://seekingalpha.com/news/3226778-tracon-pharma-launches-15m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3226778-tracon-pharma-launches-15m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226770\" data-ts=\"1479934870\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROSG-OLD\" target=\"_blank\">ROSG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226770-rosetta-to-raise-5m-via-equity-and-convertible-debt-shares-down-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosetta to raise $5M via equity and convertible debt; shares down 18%</a></h4><ul>\n<li>Thinly traded nano cap Rosetta Genomics (<a href=\"https://seekingalpha.com/symbol/ROSG-OLD\" title=\"Rosetta Genomics Ltd.\">ROSG-OLD</a> <font color=\"red\">-18.3%</font>) slumps on more than double normal volume in response to its announcement of a planned offering of stock and convertible debt expected to raise about $5M in new capital.</li>\n<li>The company has inked agreements with an unnamed institutional investor for the direct sale of 1.095M shares of common stock at $0.50, registered convertible debentures that are convertible into 6.32M shares of common, unregistered convertible debentures that are convertible into 2.585M shares of common and warrants to purchase up to 10M common shares.</li>\n<li>The debentures have a 30-year term, bear no interest and are convertible at $0.50 per common share. The five-year warrants are exercisable at $0.85 per common share. All have anti-dilution protection.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226770\" data-linked=\"Rosetta to raise $5M via equity and convertible debt; shares down 18%\" data-tweet=\"$ROSG-OLD - Rosetta to raise $5M via equity and convertible debt; shares down 18% https://seekingalpha.com/news/3226770-rosetta-to-raise-5m-via-equity-and-convertible-debt-shares-down-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3226770-rosetta-to-raise-5m-via-equity-and-convertible-debt-shares-down-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226767\" data-ts=\"1479933797\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDLI\" target=\"_blank\">PDLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226767-rbc-says-selling-in-pdl-biopharma-overdone-shares-still-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC says selling in PDL BioPharma overdone; shares still down 15%</a></h4><ul>\n<li>The potential haircut to future revenue that PDL BioPharma (<a href=\"https://seekingalpha.com/symbol/PDLI\" title=\"PDL BioPharma, Inc.\">PDLI</a> <font color=\"red\">-15.2%</font>) faces from Eli Lilly's (<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a> <font color=\"red\">-10.5%</font>) solanezumab flop was already priced into the stock says RBC's Adnan Butt. PDL was eligible to receive royalties on solanezumab sales.</li>\n<li>He calls the sell-off an \"overreaction\" and adds that the most significant near-term catalyst is Novartis' (<a href=\"https://seekingalpha.com/symbol/NVS\" title=\"Novartis AG\">NVS</a> <font color=\"green\">+1%</font>) hypertension drug Tekturna (aliskiren), which the company <a href=\"http://investor.pdl.com/releasedetail.cfm?ReleaseID=978288\" target=\"_blank\">owns a piece of</a> through its initial $75M equity investment in Noden Pharma DAC (Noden acquired global rights from Novartis). PDL expects to invest an additional $64M by next year.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226767\" data-linked=\"RBC says selling in PDL BioPharma overdone; shares still down 15%\" data-tweet=\"$PDLI $PDLI $LLY - RBC says selling in PDL BioPharma overdone; shares still down 15% https://seekingalpha.com/news/3226767-rbc-says-selling-in-pdl-biopharma-overdone-shares-still-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3226767-rbc-says-selling-in-pdl-biopharma-overdone-shares-still-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226768\" data-ts=\"1479933579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226768-deere-cruises-to-record-highs-after-earnings-rout-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deere cruises to record highs after earnings rout expectations</a></h4><ul>     <li>Deere (<a href=\"https://seekingalpha.com/symbol/DE\" title=\"Deere &amp; Company\">DE</a> <font color=\"green\">+11.3%</font>) powers to all-time highs following its easy <a href=\"https://seekingalpha.com/news/3226623-deere-soars-big-fq4-beat\" target=\"_blank\">FQ4 earnings</a> and revenue beats, as factors ranging from machinery pricing to lower  overheads spending helped it report a much smaller-than-expected decline in quarterly earnings, CFO Raj Kalathur said during today's <a href=\"https://seekingalpha.com/article/4025999-deere-and-companys-de-q4-2016-results-earnings-call-transcript\" target=\"_blank\">earnings conference call</a>.</li>     <li>DE forecasts FY 2017 sales of its farm and construction equipment <a href=\"http://ww.wsj.com/articles/deere-signals-better-performance-ahead-1479904066\" target=\"_blank\">will fall by 1% Y/Y</a>, but analysts were expecting sales to drop by ~3% after sliding 9.3% to $23.4B in 2016, and predicts next year's profit will slip by just 1% following a 21% decline in 2016 to $1.5B.</li>     <li>DE also said prices for new and used equipment firmed in the quarter, taking pressure off dealers to offer discounts that squeeze margins.</li>     <li>\"It's not that the cycle is turning, it is that they are <a href=\"http://www.reuters.com/article/us-deere-results-idUSKBN13I13V\" target=\"_blank\">managing it better than before</a>,\" Jefferies analyst Stephen Volkmann says.</li>     <li>Caterpillar (<a href=\"https://seekingalpha.com/symbol/CAT\" title=\"Caterpillar Inc.\">CAT</a> <font color=\"green\">+2.7%</font>), which has some market overlap with DE, surges to its best levels since December 2014, while AGCO (<a href=\"https://seekingalpha.com/symbol/AGCO\" title=\"AGCO Corporation\">AGCO</a> <font color=\"green\">+3.4%</font>), Lindsay, CNH Industrial (<a href=\"https://seekingalpha.com/symbol/CNHI\" title=\"CNH Industrial N.V.\">CNHI</a> <font color=\"green\">+4.7%</font>) and Tractor Supply (<a href=\"https://seekingalpha.com/symbol/TSCO\" title=\"Tractor Supply Company\">TSCO</a> <font color=\"green\">+0.8%</font>) also are higher.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3226768\" data-linked=\"Deere cruises to record highs after earnings rout expectations\" data-tweet=\"$DE $DE $CAT - Deere cruises to record highs after earnings rout expectations https://seekingalpha.com/news/3226768-deere-cruises-to-record-highs-after-earnings-rout-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3226768-deere-cruises-to-record-highs-after-earnings-rout-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226766\" data-ts=\"1479933021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVB\" target=\"_blank\">NAVB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226766-navidea-sells-lymphoseek-to-cardinal-health-for-up-to-310m-shares-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%</a></h4><ul>\n<li>Navidea Biopharmaceuticals (<a href=\"https://seekingalpha.com/symbol/NAVB\" title=\"Navidea Biopharmaceuticals\">NAVB</a> <font color=\"green\">+4.7%</font>) perks up on the <a href=\"http://www.businesswire.com/news/home/20161123005696/en/Navidea-Signs-Asset-Purchase-Agreement-Cardinal-Health\" target=\"_blank\">news </a>that it has inked an asset purchase agreement with Cardinal Health (<a href=\"https://seekingalpha.com/symbol/CAH\" title=\"Cardinal Health Inc.\">CAH</a> <font color=\"green\">+0.5%</font>) selling Lymphoseek (technetium Tc 99m tilmanocept).</li>\n<li>Under the terms of the deal, Navidea will receive $80M at closing and up to $230M in milestones through 2026, with $20.1M guaranteed over the next three years. Also, Cardinal will license a portion of the intellectual property back to Navidea to allow it to develop and market new immunodiagnostic and immunotherapeutic products in North America while continuing to produce and market Lymphoseek ex-North America under a different brand name.</li>\n<li>The transaction should close in Q1.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226766\" data-linked=\"Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%\" data-tweet=\"$NAVB $NAVB $CAH - Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5% https://seekingalpha.com/news/3226766-navidea-sells-lymphoseek-to-cardinal-health-for-up-to-310m-shares-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3226766-navidea-sells-lymphoseek-to-cardinal-health-for-up-to-310m-shares-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>122&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226776\" data-ts=\"1479932123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLNG\" target=\"_blank\">GLNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226776-golar-lng-started-buy-gaslog-neutral-seaport-global\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golar LNG started at Buy, GasLog at Neutral by Seaport Global</a></h4><ul>     <li>Golar LNG (<a href=\"https://seekingalpha.com/symbol/GLNG\" title=\"Golar LNG Limited\">GLNG</a> <font color=\"green\">+1.8%</font>) is initiated with a <a href=\"http://www.nasdaq.com/article/energy-sector-update-for-11232016-glngarlpenbl-cm713412\" target=\"_blank\">Buy recommendation</a> and a $35 price target, while GasLog (<a href=\"https://seekingalpha.com/symbol/GLOG\" title=\"GasLog\">GLOG</a> <font color=\"green\">+0.1%</font>) is started with a <a href=\"http://www.streetinsider.com/Analyst+Comments/Seaport+Global+Securities+Starts+GasLog+Ltd.+%28GLOG%29+at+Neutral/12279813.html\" target=\"_blank\">Neutral rating</a> and an $18 target at Seaport Global.</li>     <li>The firm believes the liquefied natural gas shipping market is in the early stages of a multi-year recovery, driven by new LNG projects in Australia and the U.S., and that GLNG and GLOG are well positioned for a recovery because of their high quality fleet and strong financial platform, with 79% of its fleet employed on long-term charters with a blue-chip customer base that provide sound earnings visibility.</li>\n<li>Seaport believes GLOG shares are fairly valued at a 22.8% premium to its adjusted NAV estimate, but the potential recovery in the LNG shipping market as well as an expansion into the FSRU market could serve as potential catalysts.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226776\" data-linked=\"Golar LNG started at Buy, GasLog at Neutral by Seaport Global\" data-tweet=\"$GLNG $GLNG $GLOG - Golar LNG started at Buy, GasLog at Neutral by Seaport Global https://seekingalpha.com/news/3226776-golar-lng-started-buy-gaslog-neutral-seaport-global?source=tweet\" data-url=\"https://seekingalpha.com/news/3226776-golar-lng-started-buy-gaslog-neutral-seaport-global\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226762\" data-ts=\"1479931572\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVB\" target=\"_blank\">NAVB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226762-trading-in-navidea-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading in Navidea halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Navidea Biopharmaceuticals (<a href='https://seekingalpha.com/symbol/NAVB' title='Navidea Biopharmaceuticals'>NAVB</a> <font color='green'>+2.4%</font>) pending news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3226762\" data-linked=\"Trading in Navidea halted pending news\" data-tweet=\"$NAVB - Trading in Navidea halted pending news https://seekingalpha.com/news/3226762-trading-in-navidea-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3226762-trading-in-navidea-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226757\" data-ts=\"1479931209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226757-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AVNW' title='Aviat Networks, Inc.'>AVNW</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/QADA' title='QAD Inc'>QADA</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/QADB' title='QAD Inc'>QADB</a> <font color='green'>+15%</font>. STV <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/VEEV' title='Veeva Systems Inc.'>VEEV</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NMBL' title='Nimble Storage, Inc.'>NMBL</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/TSRI' title='TSR, Inc.'>TSRI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3226757\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$AVNW $QADA $QADB - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3226757-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3226757-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226761\" data-ts=\"1479931075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226761-freeport-says-debt-reduction-plan-now-complete-1_5b-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport says debt reduction plan now complete with $1.5B offering</a></h4><ul>     <li>Freeport McMoRan (<a href=\"https://seekingalpha.com/symbol/FCX\" title=\"Freeport-McMoRan Inc.\">FCX</a> <font color=\"green\">+6.6%</font>) surges to 16-month highs after saying it <a href=\"http://www.reuters.com/article/us-freeport-mcmoran-debt-idUSKBN13I1SY\" target=\"_blank\">raised $1.5B in an equity offering</a> to complete its plan to reduce debt with proceeds from asset sales and new equity.</li>     <li>FCX, which has sold mining and energy assets in deals worth $6.6B YTD, says it can now meet its debt reduction target of $5B-$10B; it had $19B in debt as  of Sept. 30.</li>\n<li>FCX says it sold 116.5M shares since July 28 under the offering and  now has ~1.44B common shares outstanding.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3226761\" data-linked=\"Freeport says debt reduction plan now complete with $1.5B offering\" data-tweet=\"$FCX - Freeport says debt reduction plan now complete with $1.5B offering https://seekingalpha.com/news/3226761-freeport-says-debt-reduction-plan-now-complete-1_5b-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3226761-freeport-says-debt-reduction-plan-now-complete-1_5b-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226744\" data-ts=\"1479924001\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226744-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MARPS' title='Marine Petroleum Trust'>MARPS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CFFI' title='C&F Financial Corporation'>CFFI</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ZAIS' title='ZAIS Group Holdings'>ZAIS</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BCRH' title='Blue Capital Reinsurance Holdings Ltd.'>BCRH</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3226744\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$MARPS $CFFI $MSB - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3226744-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3226744-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226735\" data-ts=\"1479923181\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226735-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+61%</font>. <a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/SPEX' title='Spherix Incorporated'>SPEX</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+14%</font>. STV <font color='green'>+15%</font>. PARN <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/AVNW' title='Aviat Networks, Inc.'>AVNW</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='red'>-30%</font>. SKLN <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-27%</font>. RXII <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/ACIU' title='AC Immune SA'>ACIU</a> <font color='red'>-15%</font>. OPXA <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NMBL' title='Nimble Storage, Inc.'>NMBL</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='red'>-14%</font>. MIRN <font color='red'>-13%</font>. &nbsp; <a href='https://seekingalpha.com/symbol/CXRX-OLD' title='Concordia International Corp'>CXRX-OLD</a>&nbsp;<font color='red'>-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3226735\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ESEA $SINO $SPEX - Midday Gainers / Losers https://seekingalpha.com/news/3226735-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3226735-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226734\" data-ts=\"1479923148\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPE\" target=\"_blank\">HPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226734-hewlett-packard-enterprise-coverage-holds-mostly-confident-post-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hewlett Packard Enterprise coverage holds mostly confident post-Q4</a></h4><ul>\n<li>Associated bullish ratings are reissued today at <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734168/pullback-in-hewlett-packard-enterprise-creates-opportuni\" target=\"_blank\">Bernstein</a> (target $24), <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733903/investors-could-be-underappreciating-the-free-cash-flow-\" target=\"_blank\">Citi</a> ($25 to $27), <a href=\"http://thefly.com/landingPageNews.php?id=2467622&amp;headline=HPE;CSCO-HP-Enterprise-Cisco-analyst-commentary-\" target=\"_blank\">Oppenheimer &amp; Co.</a> ($25) and <a href=\"http://thefly.com/landingPageNews.php?id=2467614&amp;headline=HPE-HP-Enterprise-analyst-commentary-\" target=\"_blank\">UBS</a> ($24.50 to $26), though not all analysts are so encouraged, as Barclays' Mark Moskowitz <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8734820/expect-hewlett-packard-enterprise-shares-to-stay-under-p\" target=\"_blank\">remains Underweight</a> with an $18 target on attributed industry-wide legacy vendor issues.</li>\n<li>Following the reporting, Hewlett Packard Enterprise (NYSE:<a href=\"https://seekingalpha.com/symbol/HPE\" title=\"Hewlett Packard Enterprise\">HPE</a>) shares are to $23.29, <font color=\"green\">higher by 1.84%</font> on today's session and relatively unmoved (<font color=\"red\">-0.85%</font>) on a 5-day basis.</li>\n<li>Previously \u2013 <a href=\"https://seekingalpha.com/news/3226527-hewlett-packard-enterprise-q4-revenue-forecasts-eps-slightly-minus-1_6-percent-hours\" target=\"_blank\">Hewlett Packard Enterprise Q4 revenue off forecasts, EPS slightly over; -1.6% after hours</a> / <a href=\"https://seekingalpha.com/article/4025732-hewlett-packard-enterprises-hpe-ceo-meg-whitman-q4-2016-results-earnings-call-transcript\" target=\"_blank\">earnings call transcript</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226734\" data-linked=\"Hewlett Packard Enterprise coverage holds mostly confident post-Q4\" data-tweet=\"$HPE - Hewlett Packard Enterprise coverage holds mostly confident post-Q4 https://seekingalpha.com/news/3226734-hewlett-packard-enterprise-coverage-holds-mostly-confident-post-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3226734-hewlett-packard-enterprise-coverage-holds-mostly-confident-post-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226729\" data-ts=\"1479921432\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226729-natural-gas-futures-react-to-smaller-expected-inventory-draw\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas futures react to smaller than expected inventory draw</a></h4><ul>\n<li>\n<a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory</a>: <strong>-2</strong><strong> Bcf</strong> vs. +5 Bcf consensus, +30 Bcf last week.</li>\n<li>Futures <font color=\"green\">+1.64%</font> to $3.032.</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/UNG\" title=\"The United States Natural Gas ETF, LP\">UNG</a>, <a href=\"https://seekingalpha.com/symbol/DGAZ\" title=\"VelocityShares 3x Inverse Natural Gas ETN\">DGAZ</a>, <a href=\"https://seekingalpha.com/symbol/UGAZ\" title=\"VelocityShares 3x Long Natural Gas ETN\">UGAZ</a>, <a href=\"https://seekingalpha.com/symbol/BOIL\" title=\"ProShares Ultra Bloomberg Natural Gas ETF\">BOIL</a>, <a href=\"https://seekingalpha.com/symbol/GAZ\" title=\"iPath DJ-UBS Natural Gas Total Return Sub-Index ETN\">GAZ</a>, <a href=\"https://seekingalpha.com/symbol/KOLD\" title=\"ProShares UltraShort Bloomberg Natural Gas ETF\">KOLD</a>, <a href=\"https://seekingalpha.com/symbol/UNL\" title=\"The United States 12 Month Natural Gas ETF, LP\">UNL</a>, <a href=\"https://seekingalpha.com/symbol/DCNG\" title=\"iPath Pure Beta Seasonal Natural Gas ETN\">DCNG</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226729\" data-linked=\"Natural gas futures react to smaller than expected inventory draw\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas futures react to smaller than expected inventory draw https://seekingalpha.com/news/3226729-natural-gas-futures-react-to-smaller-expected-inventory-draw?source=tweet\" data-url=\"https://seekingalpha.com/news/3226729-natural-gas-futures-react-to-smaller-expected-inventory-draw\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226727\" data-ts=\"1479920748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226727-euroseas-announces-acquisition-and-short-term-loan-facility-sharesplus-57\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Euroseas announces acquisition and Short-term loan facility; shares +57%</a></h4><ul>     <li>Euroseas (ESEA <font color=\"green\">+57%</font>) announced that it signed a memorandum of agreement to purchase the M/V Capetan Tassos, a Panamax size drybulk carrier of 75,100 dwt built in 2000 in Japan for ~$4.4M. The vessel is expected to be delivered to the Company in January 2017.</li>     <li>The Company also announced that it reached an agreement with a company affiliated with its CEO to draw a $2M loan to finance working capital needs.The loan matures in Jan. 2018. Interest on loan is payable quarterly and there are no principal repayments until loan matures.</li>     <li>CEO Aristides Pittas: \"We are very pleased to announce the acquisition of M/V Capetan Tassos as we believe the sector is approaching a turning point after a long period of depressed rates. Furthermore, to facilitate the acquisition and provide additional working capital, we arranged for a short term loan with an affiliated party; the loan was negotiated by an independent committee of our Board of Directors and carries what we believe to be better-than market terms.\"</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3226727\" data-linked=\"Euroseas announces acquisition and Short-term loan facility; shares +57%\" data-tweet=\"Euroseas announces acquisition and Short-term loan facility; shares +57% https://seekingalpha.com/news/3226727-euroseas-announces-acquisition-and-short-term-loan-facility-sharesplus-57?source=tweet\" data-url=\"https://seekingalpha.com/news/3226727-euroseas-announces-acquisition-and-short-term-loan-facility-sharesplus-57\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226726\" data-ts=\"1479920452\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226726-consumer-goods-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer Goods - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/CAL\" title=\"Caleres, Inc.\">CAL</a> <font color=\"green\">+15%</font>. <a href=\"https://seekingalpha.com/symbol/PME\" title=\"Pingtan Marine Enterprise Ltd.\">PME</a> <font color=\"green\">+11%</font>. <a href=\"https://seekingalpha.com/symbol/OBCI\" title=\"Ocean Bio-Chem, Inc.\">OBCI</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/NTZ\" title=\"Natuzzi S.p.A.\">NTZ</a> <font color=\"green\">+8%</font>. <a href=\"https://seekingalpha.com/symbol/CAAS\" title=\"China Automotive Systems, Inc.\">CAAS</a> <font color=\"green\">+7%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/NVFY\" title=\"Nova Lifestyle, Inc.\">NVFY</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/CVGW\" title=\"Calavo Growers, Inc.\">CVGW</a> <font color=\"red\">-6%</font>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226726\" data-linked=\"Consumer Goods - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$CAL $PME $OBCI - Consumer Goods - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3226726-consumer-goods-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3226726-consumer-goods-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226723\" data-ts=\"1479919844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEEV\" target=\"_blank\">VEEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226723-j-p-morgan-canaccord-genuity-raise-targets-on-veeva-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.P. Morgan, Canaccord Genuity raise targets on Veeva Systems</a></h4><ul>\n<li>\n<a href=\"http://thefly.com/landingPageNews.php?id=2467544&amp;headline=VEEV-Veeva-analyst-commentary-\" target=\"_blank\">J.P. Morgan</a> moves from $45 to $50, <a href=\"http://thefly.com/landingPageNews.php?id=2467613&amp;headline=VEEV-Veeva-analyst-commentary-at-Canaccord\" target=\"_blank\">Canaccord Genuity</a> from $46 to $48 while maintaining respective Overweight and Buy ratings. On the strong reporting, Veeva Systems' (NYSE:<a href=\"https://seekingalpha.com/symbol/VEEV\" title=\"Veeva Systems Inc.\">VEEV</a>) shares are trading at <font color=\"green\">9.2% gains</font> to $45.39.</li>\n<li>Previously \u2013 <a href=\"https://seekingalpha.com/news/3226532-veeva-systems-plus-6_35-percent-q3-results-outlook-encouraging\" target=\"_blank\">Veeva Systems +6.35%; Q3 results, outlook encouraging</a> / <a href=\"http://seekingalpha.com/article/4025721-veeva-systems-veev-ceo-peter-gassner-q3-2017-results-earnings-call-transcript\" target=\"_blank\">earnings call transcript</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226723\" data-linked=\"J.P. Morgan, Canaccord Genuity raise targets on Veeva Systems\" data-tweet=\"$VEEV - J.P. Morgan, Canaccord Genuity raise targets on Veeva Systems https://seekingalpha.com/news/3226723-j-p-morgan-canaccord-genuity-raise-targets-on-veeva-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3226723-j-p-morgan-canaccord-genuity-raise-targets-on-veeva-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226720\" data-ts=\"1479919422\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRB\" target=\"_blank\">CLRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226720-cellectar-bio-prices-equity-offering-shares-down-32\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectar Bio prices equity offering; shares down 32%</a></h4><ul>\n<li>Thinly traded nano cap Cellectar Biosciences (<a href=\"https://seekingalpha.com/symbol/CLRB\" title=\"Cellectar Biosciences, Inc.\">CLRB</a> <font color=\"red\">-31.5%</font>) slumps on more than a 6x surge in volume in response to the pricing of its public offering of common stock. It plans to raise $8M via the offering of common stock or, instead, shares of preferred stock that are convertible into 66,667 shares of common at an effective price of $1.50 (~$100K/preferred share).</li>\n<li>With each common share acquired, buyers will receive one immediately exercisable five-year warrant to purchase one share of common at $1.50.</li>\n<li>Net proceeds of ~$7.2M will fund working capital and general corporate purposes.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226720\" data-linked=\"Cellectar Bio prices equity offering; shares down 32%\" data-tweet=\"$CLRB - Cellectar Bio prices equity offering; shares down 32% https://seekingalpha.com/news/3226720-cellectar-bio-prices-equity-offering-shares-down-32?source=tweet\" data-url=\"https://seekingalpha.com/news/3226720-cellectar-bio-prices-equity-offering-shares-down-32\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226714\" data-ts=\"1479917710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHC\" target=\"_blank\">BHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226714-mizuho-sees-35-downside-valeant-downgrades-to-underperform-shares-slump-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mizuho sees 35% downside with Valeant, downgrades to Underperform; shares slump 6%</a></h4><ul>\n<li>Valeant Pharmaceuticals (VRX <font color=\"red\">-5.8%</font>) doesn't have many supporters among sell-side analysts. Mizuho Securities just downgraded it to Underperform from Neutral and lowered the price target to $11 (35% downside risk) from $25. It's quite a reversal for analyst Irina Koffler. Last year she had a $155 price target on the stock.</li>\n<li>Out of 13 analysts, only three have a bullish rating on the stock. Most are neutral. Only one other shop, Wells Fargo, rates its Underperform.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226714\" data-linked=\"Mizuho sees 35% downside with Valeant, downgrades to Underperform; shares slump 6%\" data-tweet=\"$BHC - Mizuho sees 35% downside with Valeant, downgrades to Underperform; shares slump 6% https://seekingalpha.com/news/3226714-mizuho-sees-35-downside-valeant-downgrades-to-underperform-shares-slump-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3226714-mizuho-sees-35-downside-valeant-downgrades-to-underperform-shares-slump-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>128&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226708\" data-ts=\"1479916841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226708-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PHMD' title='PhotoMedex, Inc.'>PHMD</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/HTBX' title='Heat Biologics, Inc.'>HTBX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/USNA' title='USANA Health Sciences Inc.'>USNA</a> <font color='red'>-51%</font>. <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='red'>-32%</font>. SKLN <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a> <font color='red'>-25%</font>. RXII <font color='red'>-17%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3226708\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$MDGS $PHMD $HTBX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3226708-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3226708-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226704\" data-ts=\"1479916480\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PNNT\" target=\"_blank\">PNNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226704-no-bounce-for-pennantpark-investment-fbr-throws-in-towel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No bounce for PennantPark Investment; FBR throws in the towel</a></h4><ul>\n<li>Analyst Christopher Nolan doesn't believe the company will be able to materially narrow the sizable discount to peers it's trading at following this week's earnings miss and big dividend cut.</li>\n<li>He downgrades PennantPark (<a href=\"https://seekingalpha.com/symbol/PNNT\" title=\"PennantPark Investment\">PNNT</a> <font color=\"red\">-1.8%</font>) to Market Perform from Outperform. The $8 price target remains (<font color=\"green\">11% upside</font>).</li>\n<li>Source: <a href=\"http://thefly.com/landingPageNews.php?id=2467563&amp;headline=PNNT-PennantPark-rating-change-at-FBR-Capital\" target=\"_blank\">TheFly</a>\n</li>\n<li>Speaking on the earnings call (<a href=\"https://seekingalpha.com/article/4025660-pennantpark-investments-pnnt-ceo-arthur-penn-q4-2016-results-earnings-call-transcript?part=single\" target=\"_blank\">transcript</a>); CEO Arthur Penn says the company needs more time to maximize the recovery on the energy portfolio, and notes the challenge of finding attractive risk-adjusted returns in the current low-yield environment.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226704\" data-linked=\"No bounce for PennantPark Investment; FBR throws in the towel\" data-tweet=\"$PNNT - No bounce for PennantPark Investment; FBR throws in the towel https://seekingalpha.com/news/3226704-no-bounce-for-pennantpark-investment-fbr-throws-in-towel?source=tweet\" data-url=\"https://seekingalpha.com/news/3226704-no-bounce-for-pennantpark-investment-fbr-throws-in-towel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226697\" data-ts=\"1479915102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226697-crude-inventory-falls-down-after-rising-for-weeks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory falls down after rising for weeks</a></h4><ul>\n<li>\n<a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>:</li>\n<li>Crude <strong>-1.3</strong><strong>M</strong> barrels vs. +0.7M consensus, +5.3M last week.</li>\n<li>Gasoline <strong>+2.3</strong><strong>M</strong> barrels vs. +0.6M consensus, +0.7M last week.</li>\n<li>Distillates <strong>+0.3M</strong> barrels vs. -0.4M consensus, +0.3M last week.</li>\n<li>Futures <font color=\"green\">+0.2% </font>to $48.12.</li>\n<li>ETFs:<a href=\"https://seekingalpha.com/symbol/USO\" title=\"The United States Oil ETF, LP\">USO</a>,                  <a href=\"https://seekingalpha.com/symbol/OIL\" title=\"iPath S&amp;P Crude Oil Total Return Index ETN\">OIL</a>, <a href=\"https://seekingalpha.com/symbol/UCO\" title=\"ProShares Ultra Bloomberg Crude Oil ETF\">UCO</a>, <a href=\"https://seekingalpha.com/symbol/SCO\" title=\"ProShares UltraShort Bloomberg Crude Oil ETF\">SCO</a>, <a href=\"https://seekingalpha.com/symbol/BNO\" title=\"The United States Brent Oil ETF, LP\">BNO</a>, <a href=\"https://seekingalpha.com/symbol/DTO\" title=\"DB Crude Oil Double Short ETN\">DTO</a>, <a href=\"https://seekingalpha.com/symbol/DBO\" title=\"PowerShares DB Oil ETF\">DBO</a>,         <a href=\"https://seekingalpha.com/symbol/UWTI\" title=\"VelocityShares 3x Long Crude Oil ETN\">UWTI</a>,          <a href=\"https://seekingalpha.com/symbol/USL\" title=\"The United States 12 Month Oil ETF, LP\">USL</a>, <a href=\"https://seekingalpha.com/symbol/DWTI\" title=\"VelocityShares 3x Inverse Crude Oil ETN\">DWTI</a>, <a href=\"https://seekingalpha.com/symbol/DNO\" title=\"The United States Short Oil ETF, LP\">DNO</a>, <a href=\"https://seekingalpha.com/symbol/SZO\" title=\"DB Crude Oil Short ETN\">SZO</a>, <a href=\"https://seekingalpha.com/symbol/OLO\" title=\"DB Crude Oil Long ETN\">OLO</a>,         <a href=\"https://seekingalpha.com/symbol/OLEM\" title=\"iPath Pure Beta Crude Oil ETN\">OLEM</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226697\" data-linked=\"Crude inventory falls down after rising for weeks\" data-tweet=\"$USO $OIL $UCO - Crude inventory falls down after rising for weeks https://seekingalpha.com/news/3226697-crude-inventory-falls-down-after-rising-for-weeks?source=tweet\" data-url=\"https://seekingalpha.com/news/3226697-crude-inventory-falls-down-after-rising-for-weeks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226696\" data-ts=\"1479915019\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226696-gold-tumbles-below-1200-rates-dollar-and-consumer-sentiment-all-surge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold tumbles below $1,200 as rates, dollar, and consumer sentiment all surge</a></h4><ul>\n<li>We'll get today's weakish data out of the way first - jobless claims unexpectedly jumped last week, and<a href=\"https://seekingalpha.com/news/3226682-new-home-sales-disappoint\" target=\"_blank\"> new home sales disappointed</a> in October (and Sept.'s print was revised lower).</li>\n<li>On the other hand, there was an unexpected<a href=\"https://seekingalpha.com/news/3226690-trump-bump-consumer-sentiment-pops-higher-post-election\" target=\"_blank\"> big lift in</a> consumer sentiment since the election, durable goods for October, surprised to the upside, and the 10-year Treasury yield <a href=\"https://seekingalpha.com/news/3226677-treasury-rout-back\" target=\"_blank\">has popped to</a> more than a one-year high of 2.39%.</li>\n<li>The dollar index has surged to its highest level <a href=\"http://finviz.com/futures_charts.ashx?t=DX&amp;p=m1\" target=\"_blank\">in about a decade</a>, with particular strength against the yen (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/FXY\" title=\"CurrencyShares Japanese Yen Trust ETF\">FXY</a>) and euro (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/FXE\" title=\"CurrencyShares Euro Trust ETF\">FXE</a>). <a href=\"https://seekingalpha.com/symbol/UUP\" title=\"PowerShares DB USD Bull ETF\">UUP</a> <font color=\"green\">+0.7%</font>\n</li>\n<li>Gold, on the other hand, continues its big retreat, <font color=\"red\">down 2.15%</font> to $1,185 per ounce - its lowest price since February. <a href=\"https://seekingalpha.com/symbol/GLD\" title=\"SPDR Gold Trust ETF\">GLD</a> <font color=\"red\">-2.15%</font>\n</li>\n<li>ETFs: <a href=\"https://seekingalpha.com/symbol/GLD\" title=\"SPDR Gold Trust ETF\">GLD</a>, <a href=\"https://seekingalpha.com/symbol/IAU\" title=\"iShares Gold Trust ETF\">IAU</a>, <a href=\"https://seekingalpha.com/symbol/UUP\" title=\"PowerShares DB USD Bull ETF\">UUP</a>, <a href=\"https://seekingalpha.com/symbol/PHYS\" title=\"Sprott Physical Gold Trust\">PHYS</a>, <a href=\"https://seekingalpha.com/symbol/SGOL\" title=\"ETFS Physical Swiss Gold Trust ETF\">SGOL</a>, <a href=\"https://seekingalpha.com/symbol/UGL\" title=\"ProShares Ultra Gold ETF\">UGL</a>, <a href=\"https://seekingalpha.com/symbol/UDN\" title=\"PowerShares DB USD Bear ETF\">UDN</a>, <a href=\"https://seekingalpha.com/symbol/DGP\" title=\"DB Gold Double Long ETN\">DGP</a>, <a href=\"https://seekingalpha.com/symbol/GTU\" title=\"Central Gold-Trust\">GTU</a>, <a href=\"https://seekingalpha.com/symbol/UGLD\" title=\"VelocityShares 3x Long Gold ETN\">UGLD</a>, <a href=\"https://seekingalpha.com/symbol/GLL\" title=\"ProShares UltraShort Gold ETF\">GLL</a>, <a href=\"https://seekingalpha.com/symbol/DZZ\" title=\"DB Gold Double Short ETN\">DZZ</a>, <a href=\"https://seekingalpha.com/symbol/GLDI\" title=\"Credit Suisse Gold Shares Covered Call ETN\">GLDI</a>, <a href=\"https://seekingalpha.com/symbol/OUNZ\" title=\"VanEck Merk Gold Trust ETF\">OUNZ</a>, <a href=\"https://seekingalpha.com/symbol/DGL\" title=\"PowerShares DB Gold ETF\">DGL</a>, <a href=\"https://seekingalpha.com/symbol/DGZ\" title=\"DB Gold Short ETN\">DGZ</a>, <a href=\"https://seekingalpha.com/symbol/DGLD\" title=\"VelocityShares 3x Inverse Gold ETN\">DGLD</a>, <a href=\"https://seekingalpha.com/symbol/USDU\" title=\"WisdomTree Bloomberg U.S. Dollar Bullish ETF\">USDU</a>, <a href=\"https://seekingalpha.com/symbol/GYEN\" title=\"AdvisorShares Gartman Gold/Yen ETF\">GYEN</a>, <a href=\"https://seekingalpha.com/symbol/GEUR\" title=\"AdvisorShares Gartman Gold/Euro ETF\">GEUR</a>, <a href=\"https://seekingalpha.com/symbol/UBG\" title=\"UBS ETRACS CMCI Gold Total Return ETN\">UBG</a>, <a href=\"https://seekingalpha.com/symbol/QGLDX\" title=\"The Gold Bullion Strategy Fund Inv\">QGLDX</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226696\" data-linked=\"Gold tumbles below $1,200 as rates, dollar, and consumer sentiment all surge\" data-tweet=\"$FXY $FXE $UUP - Gold tumbles below $1,200 as rates, dollar, and consumer sentiment all surge https://seekingalpha.com/news/3226696-gold-tumbles-below-1200-rates-dollar-and-consumer-sentiment-all-surge?source=tweet\" data-url=\"https://seekingalpha.com/news/3226696-gold-tumbles-below-1200-rates-dollar-and-consumer-sentiment-all-surge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226684\" data-ts=\"1479914033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVCN\" target=\"_blank\">NVCN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226684-class-action-lawsuit-against-neovasc-dismissed-shares-up-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Class action lawsuit against Neovasc dismissed; shares up 14%</a></h4><ul>\n<li>Nano cap Neovasc (<a href=\"https://seekingalpha.com/symbol/NVCN\" title=\"Neovasc Inc.\">NVCN</a> <font color=\"green\">+13.7%</font>) perks up on modestly higher volume in response to its <a href=\"http://www.prnewswire.com/news-releases/neovasc-announces-dismissal-of-class-action-lawsuit-602637565.html\" target=\"_blank\">announcement </a>that the U.S. District Court in Massachusetts has granted its motion to dismiss the class action lawsuit <em>Grobler v. Neovasc, et al.</em> (Civil Action No. 16-11038-RGS). The court ruled in favor of the company and its officers on all claims and ordered the case closed.</li>\n<li>Various law firms descended on the company after shares plunged when the company lost a patent case against Edwards Lifesciences (<a href=\"https://seekingalpha.com/symbol/EW\" title=\"Edwards Lifesciences Corp\">EW</a> <font color=\"green\">+1.6%</font>) unit CardiAQ earlier this year related to the Tiara valve replacement device.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/3219128-neovasc-gets-thumped-patent-case-hook-91m-shares-plummet-41-percent\" target=\"_blank\">Neovasc gets thumped in patent case, on the hook for $91M; shares plummet 41%</a> (Nov. 1)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226684\" data-linked=\"Class action lawsuit against Neovasc dismissed; shares up 14%\" data-tweet=\"$NVCN $NVCN $EW - Class action lawsuit against Neovasc dismissed; shares up 14% https://seekingalpha.com/news/3226684-class-action-lawsuit-against-neovasc-dismissed-shares-up-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3226684-class-action-lawsuit-against-neovasc-dismissed-shares-up-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226680\" data-ts=\"1479913087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTSH\" target=\"_blank\">CTSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226680-cognizant-technology-solutions-downgraded-to-market-perform-william-blair\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cognizant Technology Solutions downgraded to Market Perform at William Blair</a></h4><ul>\n<li>Analyst Anil Doradla <a href=\"http://blogs.barrons.com/techtraderdaily/2016/11/23/cognizant-william-blair-sees-ominous-structural-change-in-it-services/\" target=\"_blank\">moves from Outperform</a>, citing projected industry headwinds and disappointment over lack of capital returns.</li>\n<li>Cognizant Technology Solutions (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CTSH\" title=\"Cognizant Technology Solutions Corporation\">CTSH</a>) is <font color=\"red\">off 1.5%</font> early, bringing <font color=\"red\">losses to 5%</font> on the week term.</li>\n<li>Yesterday: <a href=\"https://seekingalpha.com/news/3226493-cognizant-technology-solutions-downgraded-underperform-bank-america-merrill-lynch\" target=\"_blank\">Cognizant Technology Solutions downgraded to Underperform at Bank of America Merrill Lynch</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226680\" data-linked=\"Cognizant Technology Solutions downgraded to Market Perform at William Blair\" data-tweet=\"$CTSH - Cognizant Technology Solutions downgraded to Market Perform at William Blair https://seekingalpha.com/news/3226680-cognizant-technology-solutions-downgraded-to-market-perform-william-blair?source=tweet\" data-url=\"https://seekingalpha.com/news/3226680-cognizant-technology-solutions-downgraded-to-market-perform-william-blair\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226679\" data-ts=\"1479912805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226679-jaguar-animal-health-secures-private-1m-capital-raise-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Animal Health secures private $1M capital raise; shares down 4%</a></h4><ul>\n<li>Jaguar Animal Health (<a href=\"https://seekingalpha.com/symbol/JAGX\" title=\"Jaguar Animal Health, Inc.\">JAGX</a> <font color=\"red\">-3.6%</font>) inks an <a href=\"http://www.businesswire.com/news/home/20161123005195/en/Jaguar-Animal-Health-Announces-Private-Placement-Common\" target=\"_blank\">agreement </a>with institutional investors for the sale of common stock and warrants that should produce gross proceeds of ~$1M.</li>\n<li>The specific offering is 1,666,668 shares of common stock at $0.60 plus Series A Warrants to purchase up to 1,666,668 shares of common at $0.75 plus Series B Warrants to purchase up to 1,666,668 shares of common at $0.90 and Series C Warrants to purchase up to 1,666,668 shares of common at $1.00. The terms of the Series A, Series B and Series C Warrants are five years, six months and one year, respectively.</li>\n<li>Net proceeds will fund working capital and general corporate purposes.</li>\n<li>Yesterday's close was $0.747.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226679\" data-linked=\"Jaguar Animal Health secures private $1M capital raise; shares down 4%\" data-tweet=\"$JAGX - Jaguar Animal Health secures private $1M capital raise; shares down 4% https://seekingalpha.com/news/3226679-jaguar-animal-health-secures-private-1m-capital-raise-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3226679-jaguar-animal-health-secures-private-1m-capital-raise-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226677\" data-ts=\"1479912581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226677-treasury-rout-is-back-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Treasury rout is back on</a></h4><ul>\n<li>After a bit of consolidation over the past few sessions, Treasurys have resumed their bear run in a big way, with the 10-year Treasury yield up a full seven basis points to 2.38% - the highest level in more than a year.</li>\n<li>Searching for excuses ... There's <a href=\"https://seekingalpha.com/news/3226631-eu-yields-jump-ecb-looks-ease-liquidity-pressures\" target=\"_blank\">a sizable selloff </a>in European government debt today as the ECB realizes its bond-purchase program has left the Continent without enough available government paper to function properly. There was also <a href=\"https://seekingalpha.com/news/3226651-durable-goods-orders-rise-sharply-october\" target=\"_blank\">a fast durable goods read</a> for the U.S. - but that's October data and we're practically in December.</li>\n<li>Coming up in a few minutes are New Home Sales for October and this afternoon the FOMC minutes. Short-term rate futures have priced in a 100% chance of a rate hike in December.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/TLT\" title=\"iShares 20+ Year Treasury Bond ETF\">TLT</a> <font color=\"red\">-1%</font>, <a href=\"https://seekingalpha.com/symbol/TBT\" title=\"ProShares UltraShort 20+ Year Treasury ETF\">TBT</a> <font color=\"green\">+2%</font>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226677\" data-linked=\"Treasury rout is back on\" data-tweet=\"$TLT $TBT - Treasury rout is back on https://seekingalpha.com/news/3226677-treasury-rout-is-back-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3226677-treasury-rout-is-back-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226670\" data-ts=\"1479911384\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226670-juno-stoked-selling-spreads-to-cell-therapy-firms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno-stoked selling spreads to other cell therapy firms</a></h4><ul><li>Other biotechs feeling Juno Therapeutics' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/JUNO\" title=\"Juno Therapeutics\">JUNO</a>) premarket (<font color=\"red\">-31%</font>) pain: ZIOPHARM (<font color=\"red\">-3%</font>); Bellicum Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BLCM\" title=\"Bellicum Pharmaceuticals\">BLCM</a>) (<font color=\"red\">-4%</font>); bluebird bio (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BLUE\" title=\"bluebird bio, Inc.\">BLUE</a>) (<font color=\"red\">-5%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3226670\" data-linked=\"Juno-stoked selling spreads to other cell therapy firms\" data-tweet=\"$JUNO $JUNO $BLCM - Juno-stoked selling spreads to other cell therapy firms https://seekingalpha.com/news/3226670-juno-stoked-selling-spreads-to-cell-therapy-firms?source=tweet\" data-url=\"https://seekingalpha.com/news/3226670-juno-stoked-selling-spreads-to-cell-therapy-firms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226659\" data-ts=\"1479910668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMBL\" target=\"_blank\">NMBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226659-nimble-storage-ratings-coverage-widely-unmoved-on-10-earnings-sell-off\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nimble Storage ratings coverage widely unmoved on 10% earnings sell-off</a></h4><ul>\n<li>Respective Positive, Outperform and Buy ratings are restated at <a href=\"http://www.streetinsider.com/Analyst+Comments/Nimble+Storage+%28NMBL%29%3A+Large+Account+Traction+Encouraging+-+Susquehanna/12279361.html\" target=\"_blank\">Susquehanna</a> (target $12) [well-positioned, potential takeover target], <a href=\"http://www.streetinsider.com/Analyst+Comments/BMO+Sees+Better+Margin+Leverage+Ahead+for+Nimble+Storage+%28NMBL%29/12279550.html\" target=\"_blank\">BMO Capital Markets</a> (target from $13 to $12) [all-flash array momentum, large deal metrics potential, shares undervalued] and <a href=\"http://www.streetinsider.com/Analyst+Comments/Nimble+Storage+%28NMBL%29+Weakness+Creates+Buying+Opportunity+-+Needham+%26+Company/12279379.html\" target=\"_blank\">Needham &amp; Company</a> ($12) [highlights all-flash array, views long-term potential] on the earnings reaction, with a Sector Perform rating reissued at <a href=\"http://www.streetinsider.com/Analyst+Comments/Nimble+Storage+%28NMBL%29%3A+Growth+Yes%2C+Profits+No+-+RBC/12279772.html\" target=\"_blank\">RBC Capital Markets</a>.</li>\n<li>Nimble Storage (NYSE:<a href=\"https://seekingalpha.com/symbol/NMBL\" title=\"Nimble Storage, Inc.\">NMBL</a>) shares are off pre-market to $8.30.</li>\n<li>Yesterday \u2013 <a href=\"https://seekingalpha.com/news/3226529-nimble-storage-minus-8-percent-q3-projected-q4-loss-per-share-guide-greater-consensus\" target=\"_blank\">Nimble Storage -8%; Q3 as projected, Q4 loss-per-share guide greater than consensus</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226659\" data-linked=\"Nimble Storage ratings coverage widely unmoved on 10% earnings sell-off\" data-tweet=\"$NMBL - Nimble Storage ratings coverage widely unmoved on 10% earnings sell-off https://seekingalpha.com/news/3226659-nimble-storage-ratings-coverage-widely-unmoved-on-10-earnings-sell-off?source=tweet\" data-url=\"https://seekingalpha.com/news/3226659-nimble-storage-ratings-coverage-widely-unmoved-on-10-earnings-sell-off\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226667\" data-ts=\"1479910634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226667-amyloid-focused-prothena-down-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amyloid-focused Prothena down 10% premarket</a></h4><ul>\n<li>Prothena (NASDAQ:<a href=\"https://seekingalpha.com/symbol/PRTA\" title=\"Prothena Corp plc\">PRTA</a>) slumps <font color=\"red\">10%</font> premarket on light volume in response to the Eli Lilly-stoked selling. It develops therapies to treat amyloid-related disorders.</li>\n<li>Its lead pipeline candidate is Phase 3-stage <a href=\"http://www.prothena.com/pipeline/neod001-for-al-and-aa-amyloidosis/\" target=\"_blank\">NEOD001</a>, an investigational monoclonal antibody in development for for the treatment of systemic amyloidosis.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226667\" data-linked=\"Amyloid-focused Prothena down 10% premarket\" data-tweet=\"$PRTA - Amyloid-focused Prothena down 10% premarket https://seekingalpha.com/news/3226667-amyloid-focused-prothena-down-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3226667-amyloid-focused-prothena-down-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226666\" data-ts=\"1479910617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226666-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/MDGS\" title=\"Medigus Ltd\">MDGS</a> <font color=\"green\">+34%</font>. <a href=\"https://seekingalpha.com/symbol/ESEA\" title=\"Euroseas Ltd.\">ESEA</a> <font color=\"green\">+27%</font>. <a href=\"https://seekingalpha.com/symbol/SINO\" title=\"Sino-Global Shipping America, Ltd.\">SINO</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/NSPR\" title=\"InspireMD, Inc.\">NSPR</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/DE\" title=\"Deere &amp; Company\">DE</a> <font color=\"green\">+10%</font>. <a href=\"https://seekingalpha.com/symbol/GSL\" title=\"Global Ship Lease, Inc\">GSL</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/VEEV\" title=\"Veeva Systems Inc.\">VEEV</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/DRYS\" title=\"DryShips Inc.\">DRYS</a> <font color=\"green\">+5%</font>.</li> <li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/CLRB\" title=\"Cellectar Biosciences, Inc.\">CLRB</a> <font color=\"red\">-33%</font>. <a href=\"https://seekingalpha.com/symbol/JUNO\" title=\"Juno Therapeutics\">JUNO</a> <font color=\"red\">-30%</font>. <a href=\"https://seekingalpha.com/symbol/ACIU\" title=\"AC Immune SA\">ACIU</a> <font color=\"red\">-20%</font>. SKLN <font color=\"red\">-16%</font>. <a href=\"https://seekingalpha.com/symbol/PDLI\" title=\"PDL BioPharma, Inc.\">PDLI</a> <font color=\"red\">-16%</font>. <a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a> <font color=\"red\">-15%</font>. <a href=\"https://seekingalpha.com/symbol/TCON\" title=\"Tracon Pharmaceuticals\">TCON</a> <font color=\"red\">-12%</font>. <a href=\"https://seekingalpha.com/symbol/FGP\" title=\"Ferrellgas Partners L.P\">FGP</a> <font color=\"red\">-12%</font>. <a href=\"https://seekingalpha.com/symbol/ENBL\" title=\"Enable Midstream Partners LP\">ENBL</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/NMBL\" title=\"Nimble Storage, Inc.\">NMBL</a> <font color=\"red\">-11%</font>. <a href=\"https://seekingalpha.com/symbol/URBN\" title=\"Urban Outfitters, Inc.\">URBN</a> <font color=\"red\">-10%</font>. <a href=\"https://seekingalpha.com/symbol/SCON\" title=\"Superconductor Technologies Inc.\">SCON</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/NAK\" title=\"Northern Dynasty Minerals Ltd\">NAK</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/BIIB\" title=\"Biogen Inc.\">BIIB</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/DRD\" title=\"DRDGOLD Limited\">DRD</a> <font color=\"red\">-7%</font>. <a href=\"https://seekingalpha.com/symbol/KGC\" title=\"Kinross Gold Corporation\">KGC</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/AG\" title=\"First Majestic Silver Corp.\">AG</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/SDRL\" title=\"Seadrill Limited (New)\">SDRL</a> <font color=\"red\">-6%</font>. <a href=\"https://seekingalpha.com/symbol/NG\" title=\"NovaGold Resources, Inc\">NG</a> <font color=\"red\">-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3226666\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$MDGS $ESEA $SINO - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3226666-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3226666-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226655\" data-ts=\"1479909333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226655-juno-slammed-on-suspension-of-mid-stage-study-of-lead-product-candidate-jcar015-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno slammed on suspension of mid-stage study of lead product candidate JCAR015; shares down 28% premarket</a></h4><ul>\n<li>Juno Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/JUNO\" title=\"Juno Therapeutics\">JUNO</a>) craters <font color=\"red\">28%</font> premarket on robust volume in response to its <a href=\"http://www.businesswire.com/news/home/20161123005289/en/Juno-Therapeutics-Places-JCAR015-Phase-II-ROCKET\" target=\"_blank\">announcement </a>that it has voluntarily placed a clinical hold on its Phase 2 ROCKET study assessing lead product candidate JCAR015 in adult patients with relapsed/refractory B cell acute lymphoblastic leukemia.</li>\n<li>The company took action after two patients suffered cerebral edema earlier this week. One died and the other is not expected to recover. The company has notified the FDA and will work with the agency and the Data and Safety Monitoring Board to determine the next steps.</li>\n<li>Fellow CAR-T developers Kite Pharma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/KITE\" title=\"Kite Pharma\">KITE</a>) and Cellectis (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLLS\" title=\"Cellectis S.A.\">CLLS</a>) are down <font color=\"red\">3%</font> and <font color=\"red\">5%</font>, respectively.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226655\" data-linked=\"Juno slammed on suspension of mid-stage study of lead product candidate JCAR015; shares down 28% premarket\" data-tweet=\"$JUNO $JUNO $KITE - Juno slammed on suspension of mid-stage study of lead product candidate JCAR015; shares down 28% premarket https://seekingalpha.com/news/3226655-juno-slammed-on-suspension-of-mid-stage-study-of-lead-product-candidate-jcar015-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3226655-juno-slammed-on-suspension-of-mid-stage-study-of-lead-product-candidate-jcar015-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226654\" data-ts=\"1479908678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226654-urban-outfittersminus-10-on-anemic-q3-results-wunderlich-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters -10% on &quot;anemic&quot; Q3 results; Wunderlich downgrades</a></h4><ul>     <li>Urban Outfitters (NASDAQ:<a href=\"https://seekingalpha.com/symbol/URBN\" title=\"Urban Outfitters, Inc.\">URBN</a>) <font color=\"red\">-10%</font> premarket after <a href=\"https://seekingalpha.com/news/3226547-urban-outfitters-misses-0_04-misses-revenue\" target=\"_blank\">Q3 earnings</a> came in short of estimates and comparable-store sales rose 1%, less than the analyst consensus estimate of a 1.8% gain.</li>     <li>Wunderlich <a href=\"http://thefly.com/landingPageNews.php?id=2467635&amp;headline=URBN-Wunderlich-downgrades-Urban-Outfitters-on-anemic-Q-results\" target=\"_blank\">downgrades</a> shares to Hold from Buy with a $32 price target, cut from $40, citing \"anemic\" Q3 results, slowing sales at Free People and Anthropologie and challenged gross margins despite easy comparisons.</li>\n<li>Wedbush analysts say results were disappointing across all key operating metrics and <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/11/8733510/urban-outfitters-disappointed-across-all-key-operating-m\" target=\"_blank\">likely will continue into Q4</a>; the firm rates URBN at Neutral with a $34 price target.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3226654\" data-linked=\"Urban Outfitters -10% on &quot;anemic&quot; Q3 results; Wunderlich downgrades\" data-tweet=\"$URBN - Urban Outfitters -10% on &quot;anemic&quot; Q3 results; Wunderlich downgrades https://seekingalpha.com/news/3226654-urban-outfittersminus-10-on-anemic-q3-results-wunderlich-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3226654-urban-outfittersminus-10-on-anemic-q3-results-wunderlich-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226653\" data-ts=\"1479908429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226653-lilly-stoked-premarket-selling-grabs-merck-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly-stoked premarket selling grabs Merck, shares down 3%</a></h4><ul>\n<li>Merck (NYSE:<a href=\"https://seekingalpha.com/symbol/MRK\" title=\"Merck &amp; Co Inc.\">MRK</a>) slumps <font color=\"red\">3%</font> premarket on higher-than-normal volume as the selling spreads from the disappointing Phase 3 results for Eli Lilly's (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) Alzheimer's disease (AD) candidate solanezumab.</li>\n<li>Merck's late-stage AD candidate is verubecestat (MK-8931), an inhibitor of an enzyme called BACE which plays a key role in the production of amyloid beta peptides. Inhibiting BACE is believed to decrease the formation of amyloid plaques in the brain thereby slowing the progression of AD.</li>\n<li>A Phase 3 study called <a href=\"https://clinicaltrials.gov/ct2/show/NCT01953601?term=mk-8931&amp;rank=5\" target=\"_blank\">APECS </a>is currently recruiting patients. The primary endpoint is the change from baseline to week 104 in a scale called CDR-SB (same scale Biogen is using in its late-stage studies of aducanumab). According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is May 2019. The estimated study completion date is March 2021.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226653\" data-linked=\"Lilly-stoked premarket selling grabs Merck, shares down 3%\" data-tweet=\"$MRK $MRK $LLY - Lilly-stoked premarket selling grabs Merck, shares down 3% https://seekingalpha.com/news/3226653-lilly-stoked-premarket-selling-grabs-merck-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3226653-lilly-stoked-premarket-selling-grabs-merck-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226648\" data-ts=\"1479907823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVXL\" target=\"_blank\">AVXL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226648-investors-warm-to-anavex-after-lilly-failure-solanezumab-shares-up-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors warm to Anavex after Lilly failure with solanezumab; shares up 4% premarket</a></h4><ul>\n<li>Micro cap Anavex Life Sciences (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AVXL\" title=\"Anavex Life Sciences Corp.\">AVXL</a>) is up <font color=\"green\">4%</font> premarket, albeit on only ~4,500 shares, on the heels of Eli Lilly's (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) failure with Alzheimer's disease (AD) candidate solanezumab.</li>\n<li>Anavex's lead candidate is <a href=\"http://www.anavex.com/pipeline/anavex-2-73/\" target=\"_blank\">Anavex 2-73</a>, an orally available sigma-1 receptor (S1R) agonist in development for the treatment of AD and Parkinson's disease. S1R plays a key role in modulating neurotransmission.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226648\" data-linked=\"Investors warm to Anavex after Lilly failure with solanezumab; shares up 4% premarket\" data-tweet=\"$AVXL $AVXL $LLY - Investors warm to Anavex after Lilly failure with solanezumab; shares up 4% premarket https://seekingalpha.com/news/3226648-investors-warm-to-anavex-after-lilly-failure-solanezumab-shares-up-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3226648-investors-warm-to-anavex-after-lilly-failure-solanezumab-shares-up-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226646\" data-ts=\"1479907617\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226646-twitter-heads-lower-open\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter heads lower before the open</a></h4><ul>\n<li>Twitter (NYSE:<a href=\"https://seekingalpha.com/symbol/TWTR\" title=\"Twitter, Inc.\">TWTR</a>) <font color=\"red\">-1.5%</font> premarket after OTR Global downgraded the stock to Negative from Mixed indicating that Q4 Y/Y ad spending has deteriorated vs. Q3.</li>\n<li>Earlier, Twitter briefly <a href=\"https://seekingalpha.com/news/3226589-twitter-suspends-dorseys-account-awkward\" target=\"_blank\">suspended</a> the account of Jack Dorsey, but the CEO later attributed its disappearance to a technical glitch.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226646\" data-linked=\"Twitter heads lower before the open\" data-tweet=\"$TWTR - Twitter heads lower before the open https://seekingalpha.com/news/3226646-twitter-heads-lower-open?source=tweet\" data-url=\"https://seekingalpha.com/news/3226646-twitter-heads-lower-open\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226642\" data-ts=\"1479907288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226642-lilly-stoked-selling-spreads-to-alzheimers-players\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly-stoked selling spreads to other Alzheimer&#39;s players</a></h4><ul>\n<li>The exodus from Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) over the failure of Alzheimer's disease (AD) candidate solanezumab is engulfing other players in the space other the Biogen (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BIIB\" title=\"Biogen Inc.\">BIIB</a>).</li>\n<li>AC Immune (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ACIU\" title=\"AC Immune SA\">ACIU</a>) is down <font color=\"red\">27%</font> premarket on light volume. Its lead product candidate is crenezumab, a monoclonal antibody that is designed to bind to all forms of misfolded Abeta proteins which promotes the disaggregation of plaques.</li>\n<li>Axovant Sciences (NASDAQ:<a href=\"https://seekingalpha.com/symbol/AXON\" title=\"Axovant Sciences\">AXON</a>) is down <font color=\"red\">9%</font> on light volume. Its AD candidate is intepirdine, an antagonist of the 5HT6 receptor which promotes the release of acetylcholine, a neurotransmitter essential for normal cognition.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226642\" data-linked=\"Lilly-stoked selling spreads to other Alzheimer&#39;s players\" data-tweet=\"$LLY $LLY $BIIB - Lilly-stoked selling spreads to other Alzheimer&#39;s players https://seekingalpha.com/news/3226642-lilly-stoked-selling-spreads-to-alzheimers-players?source=tweet\" data-url=\"https://seekingalpha.com/news/3226642-lilly-stoked-selling-spreads-to-alzheimers-players\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226632\" data-ts=\"1479905378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226632-biogen-down-8-premarket-on-diminished-prospects-for-alzheimers-candidate-aducanumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen down 8% premarket on diminished prospects for Alzheimer&#39;s candidate aducanumab</a></h4><ul>\n<li>Eli Lilly's (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) flop with solanezumab stokes selling in Biogen (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BIIB\" title=\"Biogen Inc.\">BIIB</a>) which is down <font color=\"red\">8%</font> premarket on average volume. The latter's candidate is Fast Track-tagged aducanumab, in Phase 3 development for the treatment of early-onset Alzheimer's disease (AD).</li>\n<li>The first Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02484547?term=aducanumab&amp;rank=2\" target=\"_blank\">EMERGE</a>, will enroll 1350 subjects. The primary endpoint is the change from baseline to week 78 in a scale called <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409562/\" target=\"_blank\">CDR-SB</a> (Clinical Dementia Rating - Sum of Boxes). According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is February 2020. The estimated study completion date is February 2022.</li>\n<li>The second Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02477800?term=aducanumab&amp;rank=3\" target=\"_blank\">ENGAGE</a>, has the same enrollment target, endpoint and treatment period as EMERGE.</li>\n<li>\n<a href=\"http://www.neurimmune.com/products/alzheimers-disease.html\" target=\"_blank\">Aducanumab </a>is a human recombinant monoclonal antibody derived from a library of B cells collected from healthy elderly subjects with no signs of cognitive impairment. In a Phase 1b study, patients receiving aducanumab showed a statistically significant reduction in beta amyloid in the brain. It is being developed under a <a href=\"http://www.neurimmune.com/newsartikel/20112007-biogen-idec-and-neurimmune-therapeutics-announce-alliance-to-develop-treatments-for-alzheimers-disease-.html\" target=\"_blank\">global deal</a> with <a href=\"http://www.neurimmune.com/company/about-neurimmune.html\" target=\"_blank\">Neurimmune</a> inked in November 2007.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226632\" data-linked=\"Biogen down 8% premarket on diminished prospects for Alzheimer&#39;s candidate aducanumab\" data-tweet=\"$LLY $LLY $BIIB - Biogen down 8% premarket on diminished prospects for Alzheimer&#39;s candidate aducanumab https://seekingalpha.com/news/3226632-biogen-down-8-premarket-on-diminished-prospects-for-alzheimers-candidate-aducanumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3226632-biogen-down-8-premarket-on-diminished-prospects-for-alzheimers-candidate-aducanumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226624\" data-ts=\"1479903458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLPH\" target=\"_blank\">BLPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226624-bellerophon-prices-equity-offering-shares-down-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellerophon prices equity offering; shares down 17% premarket</a></h4><ul>\n<li>Thinly traded nano cap Bellerophon Therapeutics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BLPH\" title=\"Bellerophon Therapeutics\">BLPH</a>) is off <font color=\"red\">17%</font> premarket on increased volume in response to the pricing of its public offering of Class A units.</li>\n<li>Each Class A unit, consisting of one share of common stock and one warrant to purchase one share of common, is priced at $0.70. Each five-year warrant is exercisable at $0.80 per common share.</li>\n<li>Gross proceeds should be ~$12M. Net proceeds will be used for general corporate purposes.</li>\n<li>Yesterday's close was $0.7501.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226624\" data-linked=\"Bellerophon prices equity offering; shares down 17% premarket\" data-tweet=\"$BLPH - Bellerophon prices equity offering; shares down 17% premarket https://seekingalpha.com/news/3226624-bellerophon-prices-equity-offering-shares-down-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3226624-bellerophon-prices-equity-offering-shares-down-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226621\" data-ts=\"1479902927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226621-lillys-solanezumab-flunks-late-stage-study-in-alzheimers-related-dementia-shares-down-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilly&#39;s solanezumab flunks late-stage study in Alzheimer&#39;s-related dementia; shares down 14% premarket; Biogen down 8% in sympathy</a></h4><ul>\n<li>A Phase 3 study, EXPEDITION3, assessing Eli Lilly's (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a>) solanezumab in people with mild dementia due to Alzheimer's disease (AD), failed to show a significant treatment effect compared to placebo as measured by a scale called ADAS-Cog14. The results favored solanezumab but the differences were small.</li>\n<li>The company is evaluating its options but will not pursue regulatory submissions for the indication. Detailed results will be presented on Thursday, December 8 at the Clinical Trials on Alzheimer's Disease meeting.</li>\n<li>Solanezumab is a monoclonal antibody that binds to forms of type of protein called <a href=\"https://en.wikipedia.org/wiki/Amyloid_beta\" target=\"_blank\">amyloid beta</a> after it is produced, allowing it to be cleared from the brain before forming <a href=\"http://www.memorylossonline.com/glossary/amyloidplaques.html\" target=\"_blank\">amyloid plaques</a>, the accumulation of which is associated with AD. Drug candidates targeting amyloid plaques have struggled to demonstrate a statistically valid functional treatment benefit, however. This is yet another example.</li>\n<li>Lilly expects to record a Q4 charge of ~$150M ($0.09/share after-tax). It will release revised 2016 guidance and its 2017 outlook on December 15 along with a conference call at 9:00 am ET instead of the previously scheduled call on January 4.</li>\n<li>Shares are down <font color=\"red\">14%</font> premarket on increased volume.</li>\n<li>Biogen (NASDAQ:<a href=\"https://seekingalpha.com/symbol/BIIB\" title=\"Biogen Inc.\">BIIB</a>) is down <font color=\"red\">8%</font> premarket on light volume. It is developing another amyloid-related monoclonal antibody for AD called aducanumab.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226621\" data-linked=\"Lilly&#39;s solanezumab flunks late-stage study in Alzheimer&#39;s-related dementia; shares down 14% premarket; Biogen down 8% in sympathy\" data-tweet=\"$LLY $LLY $BIIB - Lilly&#39;s solanezumab flunks late-stage study in Alzheimer&#39;s-related dementia; shares down 14% premarket; Biogen down 8% in sympathy https://seekingalpha.com/news/3226621-lillys-solanezumab-flunks-late-stage-study-in-alzheimers-related-dementia-shares-down-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3226621-lillys-solanezumab-flunks-late-stage-study-in-alzheimers-related-dementia-shares-down-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3226617\" data-ts=\"1479901796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DE\" target=\"_blank\">DE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3226617-deere-beats-0_50-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deere beats by $0.50, beats on revenue</a></h4><ul>\n<li>Deere (NYSE:<a href=\"https://seekingalpha.com/symbol/DE\" title=\"Deere &amp; Company\">DE</a>): FQ4 EPS of $0.90 <font color=\"green\">beats by $0.50</font>.</li>\n<li>Revenue of $6.52B (-3.0% Y/Y) <font color=\"green\">beats by $1.14B</font>.</li>\n<li>Shares <font color=\"green\">+2.1%</font> PM.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3226617\" data-linked=\"Deere beats by $0.50, beats on revenue\" data-tweet=\"$DE - Deere beats by $0.50, beats on revenue https://seekingalpha.com/news/3226617-deere-beats-0_50-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3226617-deere-beats-0_50-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:49 AM </div></div></li>","count":42,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}